AI System Achieves 100% Antibiotic Prescribing Accuracy in Clinical Trial

A peer-reviewed study published in npj Antimicrobials and Resistance has demonstrated that Ask Eolas, an AI-powered clinical decision support system developed by Eolas Medical, achieved 100% prescribing accuracy in a randomized controlled study conducted by researchers at Imperial College London, with support from the NIHR Northwest London Patient Safety Research Collaboration. This breakthrough comes at a critical time as American hospitals face mounting pressure to reduce inappropriate antibiotic use under stewardship mandates from The Joint Commission, CMS, and the CDC's National Action Plan for Combating Antibiotic-Resistant Bacteria.

According to the CDC, up to 50% of antibiotics prescribed in U.S. hospitals are unnecessary or inappropriately prescribed, contributing to more than 2.8 million antibiotic-resistant infections and over 35,000 deaths annually. The study evaluated three tools across progressively complex prescribing scenarios involving 45 clinicians: Hospital PDF Guidelines (47%), the Eolas App (60%), and Ask Eolas (100%). The improvement was statistically significant (p < 0.001). The absolute risk reduction was 53% compared to standard PDF guidelines, with a number needed to treat (NNT) of 1.9 — meaning for every two clinicians using Ask Eolas, one additional prescribing error was prevented.

Clinicians using Ask Eolas also reported substantially higher prescribing confidence and lower cognitive workload across all NASA Task Load Index domains, which is a standardized cognitive workload assessment. With Ask Eolas, clinicians ask a question in natural language and receive an answer drawn exclusively from their health system's own approved guidelines and protocols, with full source references — improving clinician access and adherence to hospital-developed and approved protocols and guidelines at the point of care.

Eolas Medical is already deployed across several leading U.S. health systems and academic medical centers including Mass General Brigham, Stanford, and Boston Children's Hospital, and is expanding antimicrobial stewardship capabilities nationwide. The company recently opened its U.S. headquarters in Cambridge, Massachusetts, and continues to build out its team to expand its reach across the U.S. market. Dr. Declan Kelly, Founder & CEO of Eolas Medical, stated that this study demonstrates how guideline-grounded AI can strengthen antimicrobial stewardship infrastructure while supporting frontline clinicians in high-pressure environments.

The full study is available for review at https://www.nature.com/articles/s41579-026-00345-2. This technology represents a significant advancement in clinical decision support systems that could substantially reduce antibiotic prescribing errors and combat the growing threat of antibiotic resistance in healthcare settings across the United States and globally.